The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Provided herein are methods, uses, and compositions for treating AF in a patient, such as a patient exhibiting heart failure with reduced ejection fraction.

Provided herein are methods, uses, and compositions for treating AF in a patient, such as a patient exhibiting heart failure with reduced ejection fraction.

The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists, comprising a) an ultrashort-effective β-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to the invention has high stability, even without the presence of additional adjuvants.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

A polypeptide composition for treating atrial fibrillation includes a polypeptide that has a sequence: fADNYTRLRKQMAVKKYLNSILN-NH.sub.2 (SEQ ID NO: 1), ##STR00001##
From an N-terminus of the polypeptide, a first amino acid (f) is a D-Phe, a second amino acid is Ala, and a third amino acid is Asp; and the peptide is linear in a solution and forms an α-helix structure after encountering a lipid bilayer.

A polypeptide composition for treating atrial fibrillation includes a polypeptide that has a sequence: fADNYTRLRKQMAVKKYLNSILN-NH.sub.2 (SEQ ID NO: 1), ##STR00001##
From an N-terminus of the polypeptide, a first amino acid (f) is a D-Phe, a second amino acid is Ala, and a third amino acid is Asp; and the peptide is linear in a solution and forms an α-helix structure after encountering a lipid bilayer.

In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.

Methods for preventing or treating diastolic dysfunction in an individual comprising administering to an individual in need of said prevention or treatment a therapeutically effective amount of a (gamma) γ-secretase modulator or inhibitor, compositions comprising a (gamma) γ-secretase modulator or inhibitor for use in treatment of diastolic dysfunction and pharmaceutical compositions comprising same.